Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

Sana Biotechnology (SANA) announced that the U.S. Food and Drug Administration granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes extrarenal ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including ...

Under plans to extend the company’s cash runway into 2026, Sana said it has halted development of its CD19-directed allogeneic CAR T-cell therapy, dubbed SC291, in cancer and will instead focus ...

SC291 is a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy. It is currently being evaluated in the company’s GLEAM trial, targeting B-cell mediated autoimmune diseases ...

Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed ...

Sana Biotechnology (SANA) announced it will prioritize future development activity for SC291, the company’s CD19-directed allogeneic CAR T cell therapy, in B-cell mediated autoimmune diseases ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...